Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.

Gholap AD, Khuspe PR, Morankar D, Hatvate NT, Thorat ND

DOI: 10.1016/j.drudis.2026.104800
Published: 2026 Sep 9
Container: Drug discovery today
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104800,
  title = {Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.},
  author = {Gholap AD and Khuspe PR and Morankar D and Hatvate NT and Thorat ND},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104800},
  url = {https://doi.org/10.1016/j.drudis.2026.104800}
}

RIS

TY  - JOUR
TI  - Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.
AU  - Gholap AD
AU  - Khuspe PR
AU  - Morankar D
AU  - Hatvate NT
AU  - Thorat ND
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104800
UR  - https://doi.org/10.1016/j.drudis.2026.104800
ER  -

APA

AD, G., PR, K., D, M., NT, H., & ND, T. (2026). Effector-cell-engaging bispecific antibodies for cancer therapeutics: Engineering precision immunity.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104800

Source records

pubmed · retrieved 2026-09-25T10:54:42.992Z